ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Promise for Recurrent Respiratory Papillomatosis: Pediatric otolaryngologists have high hopes for the HPV vaccine

by Thomas R. Collins • July 2, 2010

  • Tweet
  • Email
Print-Friendly Version

Optimism is growing that a new HPV vaccine will drastically decrease the number of cases of pediatric recurrent respiratory papillomatosis (RRP), a rare but devastating disease.

You Might Also Like

  • Pediatric Recurrent Respiratory Papillomatosis: Fighting the Battle of a Rare But Serious Disease
  • Recurrent Respiratory Papillomatosis: Much Has Been Done, but a Long Road Lies Ahead
  • Recurrent Respiratory Papillomatosis: Researchers Advancing Toward Prevention
  • Prevalence of Dysplasia with Recurrent Respiratory Papillomatosis Is High
Explore This Issue
July 2010

Regulators have proclaimed the vaccine safe, but experts on the disease and the vaccine say that more widespread use is needed to wipe out the disease. In addition, experts say, the medical culture in the U.S., traditionally hesitant with regard to adolescent vaccinations that are not mandated, might be a stumbling block.

RRP afflicts about four of every 100,000 children. Interferon and other drugs help to slow the spread of the lesions, but patients usually have to undergo multiple surgeries, sometimes dozens, to remove the lesions.

About 2,000 cases of pediatric RRP are reported each year in the U.S., almost all of them caused by the HPV 6 and HPV 11 strains.

The children at greatest risk are the firstborn children of young women who have genital warts during delivery. Still, the disease occurs in only about 0.5 percent of children whose mothers have condylomata during their pregnancies.

Two HPV vaccines, one developed by Merck and one by GlaxoSmithKline, have been approved for prevention of cervical cancer.

Use of the vaccine to prevent the spread of new lesions in those already afflicted has sparked interest among researchers, but otolaryngologists say controlled trials must be done to ground such treatment in solid science. There is growing hope, however, that preventive use of the Merck vaccine, Gardasil, can profoundly decrease the number of pediatric RRP cases. Gardasil is the only vaccine that targets HPV 6 and 11. It also protects against HPV 16 and 18, while the GlaxoSmithKline product, Cervarix, only protects against strains 16 and 18.

Beginning of the End

Michael Zacharisen, MD, a professor of pediatrics at the Medical College of Wisconsin who specializes in immunology and has studied RRP, said he hopes the vaccine is the beginning of the end for the affliction. “My impression would be that, with widespread immunization, RRP might become of historical interest only,” he said. “It’s not very common to begin with, but to those kids who have it it’s a huge problem, a chronic problem and a life-threatening problem.”

Craig Derkay, MD, professor of otolaryngology and pediatrics at Eastern Virginia Medical School and chair of the RRP Task Force, which is sponsored by the American Society of Pediatric Otolaryngology, said the vaccine should have a big effect. “If we get some herd immunity and vaccinate a large portion of the population before they become sexually active, then when their babies are born they will not be passing through birth canals that have been infected with the human papillomavirus,” he said.

Pages: 1 2 3 4 | Single Page

Filed Under: Departments, Head and Neck, Pediatric, Practice Focus Tagged With: HPV, human papillomavirus (HPV), pediatric otolaryngology, pediatrics, respiratory, sexually transmitted diseases, vaccineIssue: July 2010

You Might Also Like:

  • Pediatric Recurrent Respiratory Papillomatosis: Fighting the Battle of a Rare But Serious Disease
  • Recurrent Respiratory Papillomatosis: Much Has Been Done, but a Long Road Lies Ahead
  • Recurrent Respiratory Papillomatosis: Researchers Advancing Toward Prevention
  • Prevalence of Dysplasia with Recurrent Respiratory Papillomatosis Is High

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Otolaryngologists Have a Major Role to Play in Treating COVID-19 Long-Haulers
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.